Continuing Medical Education: Psychiatry CME: CME Outfitters: Bipolar Depression: Individualizing Treatment to Prevent Relapse and Recurrence: Online Psychiatry CME: September 10, 2008
http://www.cmenetworks.com/cme/9560/1/Continuing-Medical-Education-Psychiatry-CME-CME-Outfitters-Bipolar-Depression-Individualizing-Treatment-to-Prevent-Relapse-and-Recurrence-Online-Psychiatry-CME-September-10-2008/Page1.html
CME Outfitters
CME Outfitters is an independent accredited healthcare communications agency providing multidisciplinary continuing medical education content development, production, marketing, accreditation, and project management services to the healthcare industry.
By CME Outfitters
Published on 07/15/2008
Bipolar Depression: Individualizing Treatment to Prevent Relapse and Recurrence
CME Outfitters
September 10, 2008
There is an unmet need for acute - and in particular, maintenance - pharmacologic treatments that target bipolar depression. Despite the preponderance of depressive symptoms and episodes (versus manic) over the course of both bipolar I and II disorder, and the more frequent functional impairment associated with bipolar depression, there has been a disproportionate lack of attention paid to establishing effective treatment and management of bipolar depression. This has recently begun to change, however, with the approval and addition of atypical antipsychotics to the arsenal of medications used for bipolar depression.
Recently completed studies and trials in progress are expected to contribute to the growing literature supporting the effectiveness of these types of medications for the treatment of bipolar depression. Clinicians are in urgent need of education and performance improvement in the recognition, diagnosis, and acute and maintenance treatment of bipolar depression. Published treatment guidelines are an adequate framework for developing treatment plans. However, clinicians need additional education on pharmacologic treatments for bipolar depression. In this evidence-based, neuroscienceCME TV activity, experts will provide information on pharmacologic treatments for bipolar depression that will enable participants to integrate these findings into current treatment guidelines to further enhance and maintain good patient outcomes.
CME Outfitters
September 10, 2008
There is an unmet need for acute - and in particular, maintenance - pharmacologic treatments that target bipolar depression. Despite the preponderance of depressive symptoms and episodes (versus manic) over the course of both bipolar I and II disorder, and the more frequent functional impairment associated with bipolar depression, there has been a disproportionate lack of attention paid to establishing effective treatment and management of bipolar depression. This has recently begun to change, however, with the approval and addition of atypical antipsychotics to the arsenal of medications used for bipolar depression.
Recently completed studies and trials in progress are expected to contribute to the growing literature supporting the effectiveness of these types of medications for the treatment of bipolar depression. Clinicians are in urgent need of education and performance improvement in the recognition, diagnosis, and acute and maintenance treatment of bipolar depression. Published treatment guidelines are an adequate framework for developing treatment plans. However, clinicians need additional education on pharmacologic treatments for bipolar depression. In this evidence-based, neuroscienceCME TV activity, experts will provide information on pharmacologic treatments for bipolar depression that will enable participants to integrate these findings into current treatment guidelines to further enhance and maintain good patient outcomes.
Bipolar Depression: Individualizing Treatment to Prevent Relapse and Recurrence
CME Sponsor: CME Outfitters
Location:
This is an Interactive CE broadcast via neuroscienceCME TV
CME Course Directors/Instructors:
Mark A. Frye, MD
Professor of Psychiatry
Mayo Clinic
Director, The Mayo Mood Clinic and Research Program
Rochester, MN
Susan L. McElroy, MD
Chief of Research, Lindner Center of HOPE
Mason, OH
Professor of Psychiatry & Neuroscience
Department of Psychiatry
University of Cincinnati College of Medicine
Cincinnati, OH
Roger S. McIntyre, MD, FRCPC
Associate Professor of Psychiatry and Pharmacology
University of Toronto
Head, Mood Disorders Psychopharmacology Unit
University Health Network
Toronto, ON
Cost: Free
Number of credits:
Varies from professions. Please see the brochure.
Links
Brochure
Detailed Description:
There is an unmet need for acute - and in particular, maintenance - pharmacologic treatments that target bipolar depression. Despite the preponderance of depressive symptoms and episodes (versus manic) over the course of both bipolar I and II disorder, and the more frequent functional impairment associated with bipolar depression, there has been a disproportionate lack of attention paid to establishing effective treatment and management of bipolar depression. This has recently begun to change, however, with the approval and addition of atypical antipsychotics to the arsenal of medications used for bipolar depression.
Recently completed studies and trials in progress are expected to contribute to the growing literature supporting the effectiveness of these types of medications for the treatment of bipolar depression. Clinicians are in urgent need of education and performance improvement in the recognition, diagnosis, and acute and maintenance treatment of bipolar depression. Published treatment guidelines are an adequate framework for developing treatment plans. However, clinicians need additional education on pharmacologic treatments for bipolar depression. In this evidence-based, neuroscienceCME TV activity, experts will provide information on pharmacologic treatments for bipolar depression that will enable participants to integrate these findings into current treatment guidelines to further enhance and maintain good patient outcomes.
Location:
This is an Interactive CE broadcast via neuroscienceCME TV
CME Course Directors/Instructors:
Mark A. Frye, MD
Professor of Psychiatry
Mayo Clinic
Director, The Mayo Mood Clinic and Research Program
Rochester, MN
Susan L. McElroy, MD
Chief of Research, Lindner Center of HOPE
Mason, OH
Professor of Psychiatry & Neuroscience
Department of Psychiatry
University of Cincinnati College of Medicine
Cincinnati, OH
Roger S. McIntyre, MD, FRCPC
Associate Professor of Psychiatry and Pharmacology
University of Toronto
Head, Mood Disorders Psychopharmacology Unit
University Health Network
Toronto, ON
Cost: Free
Number of credits:
Varies from professions. Please see the brochure.
Links
Brochure
Detailed Description:
There is an unmet need for acute - and in particular, maintenance - pharmacologic treatments that target bipolar depression. Despite the preponderance of depressive symptoms and episodes (versus manic) over the course of both bipolar I and II disorder, and the more frequent functional impairment associated with bipolar depression, there has been a disproportionate lack of attention paid to establishing effective treatment and management of bipolar depression. This has recently begun to change, however, with the approval and addition of atypical antipsychotics to the arsenal of medications used for bipolar depression.
Recently completed studies and trials in progress are expected to contribute to the growing literature supporting the effectiveness of these types of medications for the treatment of bipolar depression. Clinicians are in urgent need of education and performance improvement in the recognition, diagnosis, and acute and maintenance treatment of bipolar depression. Published treatment guidelines are an adequate framework for developing treatment plans. However, clinicians need additional education on pharmacologic treatments for bipolar depression. In this evidence-based, neuroscienceCME TV activity, experts will provide information on pharmacologic treatments for bipolar depression that will enable participants to integrate these findings into current treatment guidelines to further enhance and maintain good patient outcomes.